Bionatura Journal
Ibero-American Journal of Biotechnology and Life Sciences

Editorial

AI as the Catalyst for a New Paradigm in Biomedical Research

Rolando Pajon [1*]

[1*]*Chief Medical and Scientific Officer, Biofabri S.L Pontevedra, Spain., Member of the Scientific Board, Bionatura Journal (role declared for transparency only)*

**Corresponding author. rolando.pajon@biofabri.es*

ABSTRACT

This editorial examines how artificial intelligence (AI)—including machine learning, generative AI, and natural language processing—is reshaping biomedical research and pharmaceutical R&D. It outlines distinct adoption archetypes emerging among large pharmaceutical organizations: partnership-driven acceleration through strategic technology alliances; culture-centric transformation that embeds AI into everyday scientific and operational decision-making; and production-first democratization that makes AI tools broadly usable across functions. In parallel, AI is lowering entry barriers for smaller biotech companies, enabling faster iteration in molecular design and earlier clinical translation, while cloud and federated approaches expand access to powerful pre-trained models without compromising proprietary data. The editorial also emphasizes the limiting factors that will determine whether "democratized discovery" translates into sustained impact: high-quality, interoperable data; rigorous model validation; transparency and auditability; workforce upskilling; ethical oversight; and alignment with evolving regulatory expectations. Together, these elements define a pragmatic pathway toward an AI-integrated biomedical ecosystem focused on speed, safety, and equitable innovation.

Keywords: Artificial intelligence, pharmaceuticals, biomedicine, innovation, ethics, regulation, technological alliances, drug discovery, startups, democratization.

Editorial

The shift toward an AI-integrated pharmaceutical ecosystem is no longer a peripheral strategy but a central imperative for global health innovation. The landscape of biomedical and scientific research is undergoing a fundamental transformation. While the impact of artificial intelligence (AI) may not be immediate, the current adoption of machine learning (ML), generative AI (GenAI), and natural language processing (NLP) across the value chains of major pharmaceutical entities signals a permanent shift away from traditional R&D methodologies. This transition is not simply technological but a reconfiguration of institutional agility and scientific reach[1], as evidenced by the rapid development of mRNA platforms during recent worldwide health crises .

Strategic Divergence in AI Adoption

Analysis of industry leaders discloses clear archetypes of AI integration, delivering a roadmap for organizational evolution. These strategies demonstrate how AI is being utilized to overcome the traditional "Eroom's Law" (the slowing of R&D productivity) by boosting predictive accuracy and operational speed [2,3].

- **The Partnership-Driven Efficiency Model (Pfizer):** This model focuses on a combination of internal R&D and targeted external collaborations with technology giants such as NVIDIA and AWS. Using these

partnerships, the organization has successfully compressed drug development timelines—most notably for Paxlovid—from years to just 30 days in phase 3 research.

- **The Culture-Centric Transformation Model (Moderna):** Positions AI as a core business function led by executive vision. By deploying over 3,000 customized GPTs and merging HR with IT, the organization builds a "human-AI workforce." This approach allows for the scaling of complex mRNA sequences and manufacturing protocols with a significantly leaner team than traditional pharma giants [4].
- **The Democratized Production-First Model (Sanofi):** Aims to be the first pharma company powered by AI at scale by making tools "snackable" and accessible to all employees. Platforms like the *Aily* app and *Plai* empower real-time decision intelligence across the supply chain and R&D, leveraging specialized models such as *CodonBERT* for protein engineering [5].

The Democratization of Discovery

AI is significantly leveling the playing field for small emerging biotech firms. Generative AI platforms have already enabled the first fully AI-discovered molecules to enter Phase 2 clinical trials, specifically targeting conditions such as idiopathic pulmonary fibrosis [6]. This opening up allows startups to apply tools such as *DragonFold* for atomic-resolution protein design and cloud-based federated platforms such as *TuneLab* to access powerful, pre-trained models while maintaining the privacy of their proprietary data. These advances in protein structure prediction, driven by breakthroughs such as AlphaFold, have fundamentally changed the starting point for drug discovery [7].



Figure 1. Transformation of the Biomedical R&D Model. Comparison between traditional research—centered on manual data analysis, higher entry barriers, and slower discovery/treatment cycles—and an AI-catalyzed research framework oriented to agility and personalized treatment. The diagram summarizes the shift toward "democratized discovery" while highlighting key implementation challenges, including data/algorithmic bias and ethical oversight, alongside broader requirements for

interoperability and regulatory governance. AI transparency note: The graphic layout and icon arrangement were assisted using GPAI (gpai.app); the conceptual design, scientific content, and final wording were defined, reviewed, and validated by the authors.

Handling the Challenges Ahead

Despite these advancements, the path to full AI maturity faces substantial structural hurdles. Organizations must manage the interoperability of diverse internal and external platforms to guarantee data consistency. Furthermore, shifting toward a human-AI workforce requires extensive employee education and a culture of "responsible AI" to ensure moral oversight. Finally, as AI begins to predict regulatory queries and optimize submissions, preserving transparency and compliance with evolving global standards remains a continual challenge for the industry.

CONCLUSION

The transition toward AI-enabled biomedical research is best understood as an institutional transformation rather than a purely technological upgrade. Competitive advantage will come not only from better algorithms, but from disciplined execution: interoperable data foundations, fit-for-purpose validation, and transparent governance that keeps responsibility and accountability clearly human. Organizations that treat AI as a workforce capability—supported by training, incentives, and cross-functional integration—will move from isolated pilots to scalable, reproducible impact.

At the same time, the promise of "democratized discovery" will be realized only if high standards for quality, ethics, and regulatory readiness match access to tools. As AI increasingly influences experimental prioritization, development decisions, and regulatory interactions, the sector must preserve trust through auditability, bias mitigation, and clear documentation of model intent, limits, and uncertainty. In this context, progress is measured not by speed alone, but by reliable translation into safer, more effective, and more accessible health solutions.

Funding
This research received no external funding.

Acknowledgments
The author would like to thank the *BioNatura Journal* editorial board for their support. No specific grants from public, commercial, or not-for-profit funding agencies were used for this work.

Conflicts of Interest
The author declares no conflict of interest.

Artificial Intelligence (AI) Use Declaration

Generative AI tools were used only for language/format editing and to assist in drafting Figure 1 using GPAI (gpai.app), under full human supervision. No AI was used for data generation/analysis/interpretation. Authors reviewed and verified all content and the final figure per BioNatura Journal AI policy (https://bionaturajournal.com/artificial-intelligence--ai-.html).

REFERENCES

1. Baden LR, Pajon R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389.
2. Vamathevan J, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477. doi:10.1038/s41573-019-0024-5.

3. El-Sayed SM, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2023;28(3):103483. doi:10.1016/j.drudis.2023.103483.
4. OpenAI. Moderna and OpenAI: Accelerating the development of life-saving treatments [Case Study]. 2024. Available from: https://openai.com/index/moderna/
5. Sanofi S.A. Sanofi aims to become first pharma company powered by artificial intelligence at scale [Press Release]. 2023 Jun 13.
6. Ren F, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2024;42:1-13. doi:10.1038/s41587-024-02143-0.
7. Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2.

Received: Jan 10 2026 / **Accepted:** Feb 21 2025 / **Published (online):** Mar 15 2026 (Europe/Madrid)

Citation. Pajon R. AI as the Catalyst for a New Paradigm in Biomedical Research. *BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences.* 2026;3(1):1. https://doi.org/10.70099/BJ/2026.03.01.1

Additional Information

Correspondence should be addressed to: Email: Rolando Pajon: rolando.pajon@biofabri.es

Peer Review Information
The BioNatura Journal Editorial Office internally reviewed this Editorial in accordance with the journal's policies for editorials, perspectives, and commentaries.
BioNatura Journal thanks the scientific advisors who contributed expert feedback during the editorial preparation process.
Regional editorial coordination was conducted under the BioNatura Institutional Publishing Consortium (BIPC), involving Universidad Nacional Autónoma de Honduras (UNAH), Universidad de Panamá (UP), and RELATIC (Panama).
Publisher Information
Published by **Clinical Biotec S.L. (Madrid, Spain)** as the publisher of record under the **BioNatura Institutional Publishing Consortium (BIPC)**.
Institutional co-publishers: Universidad Nacional Autónoma de Honduras (UNAH), Universidad de Panamá (UP), and RELATIC (Panama).
Places of publication: Madrid (Spain); Tegucigalpa (Honduras); Panama City (Panama).
Online ISSN: 3020-7886

Governance
For full editorial governance, co-publisher responsibilities, and consortium structure, see the **BIPC Governance Framework (PDF)** available at:
https://clinicalbiotec.com/bipc